Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Luiz Paulo José Marques, Nayanne Aguiar Mendonça, Lucas Müller, Ana Carolina Pereira Diaz André, Eugênio Pacelle Queiroz Madeira & Lygia Maria Soares Fernandes Vieira. (2020) Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes. Postgraduate Medicine 132:8, pages 697-701.
Read now
Read now
Articles from other publishers (16)
Li Zhang, Tongdan Wang, Yan Kong, Haizhen Sun, Yuling Zhang, Junmei Wang, Zhida Wang, Shan Lu, Pei Yu & Saijun Zhou. (2023) Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial. Diabetology & Metabolic Syndrome 15:1.
Crossref
Crossref
Erika AraujoIan M. BellAlexander BurckleDennis C. KoesterJames R. ManningGeorgette Castanedo, Mingshuo Zeng, T. G. Murali DharNatalie Holmberg-Douglas, Eric R. Welin, J. Robert MerrittKevin M. PeeseJoanne J. Bronson. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews
595
710
.
Eric Pasqualotto, Janine Midori Figueiredo Watanabe, Douglas Mesadri Gewehr, Raphaela da Silva Maintinguer, Simone van de Sande‐Lee, Gustavo Neves de Araujo, Fidel Silveira Leal & Carlos Eduardo Andrade Pinheiro. (2023) Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 25:7, pages 1794-1802.
Crossref
Crossref
Iwona Piątkowska-Chmiel, Mariola Herbet, Monika Gawrońska-Grzywacz, Kamil Pawłowski, Marta Ostrowska-Leśko & Jarosław Dudka. (2023) Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology 240:4, pages 983-1000.
Crossref
Crossref
Xueting Yao, Jiawei Zhou, Ling Song, Yupeng Ren, Pei Hu & Dongyang Liu. (2023) A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors. CPT: Pharmacometrics & Systems Pharmacology 12:4, pages 487-499.
Crossref
Crossref
Zhi-Chao Luo, Zi-Run Jin, Ya-Fei Jiang, Tian-Jiao Wei, Ya-Lei Cao, Zhe Zhang, Rui Wei & Hui Jiang. (2023) The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction. Asian Journal of Andrology 25:3, pages 331-338.
Crossref
Crossref
Susanne B. Nicholas, Radica Z. Alicic & Jenny Shen. (2023) Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States. Kidney Medicine 5:1, pages 100590.
Crossref
Crossref
Yongting Zhao, Xiaofang Zhang, Haihai Liang & Lihong Wang. (2022) Antidiabetic agents: Do they hit the right targets?. Frigid Zone Medicine 2:4, pages 225-243.
Crossref
Crossref
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, Maria Chiara Auriemma, Antonio Gambardella, Gabriella di Mauro, Annalisa Capuano & Giuseppe Paolisso. (2022) Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacological Research 176, pages 106062.
Crossref
Crossref
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci & Franco Arturi. (2021) Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. Frontiers in Medicine 8.
Crossref
Crossref
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis & Pantelis Sarafidis. (2020) The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry 27:39, pages 6682-6702.
Crossref
Crossref
Claudio Borghi & Alessio Bragagni. (2020) The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors. European Heart Journal Supplements 22:Supplement_L, pages L28-L32.
Crossref
Crossref
Rui Wei, Xiaona Cui, Jin Feng, Liangbiao Gu, Shan Lang, Tianjiao Wei, Jin Yang, Junling Liu, Yunyi Le, Haining Wang, Kun Yang & Tianpei Hong. (2020) Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metabolism 111, pages 154324.
Crossref
Crossref
Sushanta Bhattacharya, Akash Rathore, Deepa Parwani, Chaitali Mallick, Vivek Asati, Shivangi Agarwal, Vaibhav Rajoriya, Ratnesh Das & Sushil Kumar Kashaw. (2020) An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent. European Journal of Medicinal Chemistry 204, pages 112523.
Crossref
Crossref
Naoki Kashihara, Kengo Kidokoro & Eiichiro Kanda. (2020) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Current Opinion in Nephrology and Hypertension 29:1, pages 112-118.
Crossref
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Crossref